OncoResponse, Inc. is a clinical-stage biotechnology company leveraging a human antibody discovery platform to develop cancer immunotherapies. The company maintains corporate office operations in Houston, Texas and Seattle, Washington.
Subscribe to see OncoResponse Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OncoResponse Inc is a biopharma company headquartered in Seattle, United States. Its most recent funding round raised $6M in April 2025. Xcout tracks 17 named people at OncoResponse Inc, including Clifford J. Stocks (Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
11 more named people on record for OncoResponse Inc, with roles, board committees and tenure — see the full roster →
The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $6M | — | |
| Grant | $13.9M | 9 named | |
| SEC Form D filing | $40.6M | — | |
| Series C | $40.6M | 10 named | |
| — | $150,000 | 8 named | |
| SEC Form D filing | $19M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 20 named investors across 5 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of OncoResponse Inc's closest competitors — see the full list of competitors and alternatives →
Oncolix, Inc. is an emerging clinical-stage biopharmaceutical company headquartered in Houston, Texas. The company focuses on the development of novel cancer therapeutics.
Resonant Therapeutics, Inc. is a biotechnology company headquartered in Houston, Texas, focused on cancer therapeutic discovery based on unique insights.
OncoSenX, Inc. is a late-stage preclinical biotechnology company headquartered in Seattle, Washington. The firm specializes in developing targeted cancer therapeutics and novel drug delivery pipelines. Its oncology technology works in coordination with parent company Entos's research platforms to advance precision gene therapies.
Oncorus, Inc. was a preclinical-stage biopharmaceutical company headquartered in Andover and Cambridge, Massachusetts, focused on developing novel viral immunotherapies for cancer treatment.
ImmunoGenesis, Inc. is a clinical-stage biotechnology company headquartered in Houston, Texas, focused on re-envisioning cold tumor treatments and cancer immunotherapy research.
Diakonos Oncology is a clinical-stage immuno-oncology company founded in 2016 and headquartered in Houston, Texas. The firm is dedicated to advancing novel cancer treatments, including its lead therapeutic candidate DOC1021.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about OncoResponse Inc? Suggest a correction · Work at OncoResponse Inc? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.